NCT04689048: Assess Use of 18F-Fluciclovine for Patients With Large Brain Metastases Treated With Staged Stereotactic Radiosurgery

NCT04689048
Breast Cancer Type: HER2+, HR+ & HER2-negative, Triple Negative
Hormone Mutations: ER+, PR+
Other Mutations: 
Breast Cancer Tissue: 
Recruitment Status: Not yet recruiting
Phase 1
Drug Category: Other

Key Eligibility Criteria:

Gender: All
Age: 18 Years and older (Adult, Older Adult)
Location of Metastases: Brain
Additional Notes: Patients must have at least 1 untreated lesion greater than 2 cm in maximum diameter; Patients must have a plan for staged stereotactic radiosurgery (SSRS) by treating team
Exclusions: Patients with prior whole brain radiation therapy; Patients with leptomeningeal disease
https://ClinicalTrials.gov/show/NCT04689048

Comments are closed.

Up ↑